Literature DB >> 28490939

Measuring quality care in localized renal cell cancer: use of appropriate preoperative investigations in a population-based cohort.

N Moideen1, K H Marzouk1,2, K J Matheson1,3, L A Wood1,2,3,4.   

Abstract

INTRODUCTION: Obtaining appropriate preoperative risk-specific staging investigations for localized renal cell carcinoma (rcc) is a recognized quality indicator. The goal of the present work was to determine the use and appropriateness of preoperative investigations in patients undergoing curative surgery for rcc.
METHODS: This population-based retrospective study of patients having surgery for localized rcc recorded the use of preoperative imaging and laboratory investigations within 6 months of surgery. "Appropriate" stage-specific investigations were determined using recognized published guidelines.
RESULTS: The study cohort consisted of 544 patients with 72.8% being stage i, 18.4% being stage ii, and 8.8% being stage iii by clinical TNM (2002) criteria. In 61.6%, chest imaging was obtained by chest radiography or computed tomography (ct) within 3 months preoperatively; in 75.6%, such imaging was obtained within 6 months. Abdominal ct imaging was obtained in 97.1% of patients before surgery, with 77.5% of patients receiving such imaging within 3 months of surgery. Complete blood count, electrolytes, and creatinine were measured in 99.1% of patients, but those tests plus other recommended blood tests including calcium, alkaline phosphatase, and liver function were measured in only 17.7%.
CONCLUSIONS: In this study, most patients received appropriate abdominal imaging, but chest imaging was underutilized in the overall cohort. Despite being recommended, blood tests such as liver function, alkaline phosphatase, and calcium were completed in fewer than 2 of 10 patients. This analysis provides the groundwork for quality improvement initiatives directed to the use of preoperative investigations in localized rcc.

Entities:  

Keywords:  Renal cell carcinoma; preoperative investigations; quality indicators

Year:  2017        PMID: 28490939      PMCID: PMC5407879          DOI: 10.3747/co.24.3290

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  3 in total

Review 1.  Cancers with increasing incidence trends in the United States: 1999 through 2008.

Authors:  Edgar P Simard; Elizabeth M Ward; Rebecca Siegel; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

2.  A strategy for quality assurance in Medicare.

Authors:  K N Lohr; S A Schroeder
Journal:  N Engl J Med       Date:  1990-03-08       Impact factor: 91.245

3.  Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma.

Authors:  Lori Wood; Georg A Bjarnason; Peter C Black; Ilias Cagiannos; Daniel Yick Chin Heng; Anil Kapoor; Christian K Kollmannsberger; Forough Mohammadzadeh; Ronald B Moore; Ricardo A Rendon; Denis Soulieres; Simon Tanguay; Peter Venner; Michael Jewett; Antonio Finelli
Journal:  J Oncol Pract       Date:  2013-06-04       Impact factor: 3.840

  3 in total
  1 in total

1.  Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system.

Authors:  Ryan Sun; Rodney H Breau; Ranjeeta Mallick; Simon Tanguay; Frederic Pouliot; Anil Kapoor; Luke T Lavallée; Antonio Finelli; Alan I So; Ricardo A Rendon; Adrian S Fairey; Jean-Baptiste Lattouf; Jun Kawakami; Bimal Bhindi; Naveen S Basappa; Lori A Wood; Georg A Bjarnason; Daniel Y C Heng; Rahul K Bansal
Journal:  Can Urol Assoc J       Date:  2021-04       Impact factor: 1.862

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.